TMD8 Cells - Bone cancer cell lines
Produktgrößen
1 each
£607,00
305729-1EACH
Über dieses Produkt
- SKU:
- 305729
- Zusätzliche Namen:
- TMD-8, Tokyo Medical and Dental university 8
- CE/IVD:
- RUO
- Weitere Details:
- The TMD8 cell line is a human diffuse large B-cell lymphoma (DLBCL) model representative of the activated B-cell-like (ABC) subtype. This subtype is characterized by constitutive activation of the NF-K KappaB pathway, which is essential for cell survival. TMD8 exhibits wild-type CARD11, yet maintains strong NF-K KappaB activity, indicating a dependency on chronic active B-cell receptor (BCR) signaling. This dependency is supported by experimental evidence showing that knockdown of BCR pathway components-including BTK, CD79A, CD79B, and IgM-leads to cell death in TMD8 cells. Additionally, TMD8 harbors a Y196H mutation in the ITAM domain of CD79B, a mutation commonly found in ABC-DLBCLs that enhances surface BCR expression and attenuates negative feedback from Lyn kinase, thus promoting sustained signaling activity. TMD8 cells also demonstrate notable sensitivity to BCL-2 inhibition via venetoclax when expressing high levels of the BCL-2 protein. However, resistance to venetoclax in such cells can be mediated by activation of the PI3K/AKT pathway, particularly following prolonged drug exposure. This resistance mechanism involves a reduction in PTEN expression and increased AKT phosphorylation. TMD8 cells with acquired resistance to venetoclax exhibit heightened susceptibility to pharmacological PI3K/AKT pathway inhibition, making them a suitable model for studying therapeutic combinations aimed at overcoming resistance in aggressive B-cell lymphomas.
- Versandbedingungen:
- Dry Ice
- Lagerbedingungen:
- Liquid N2, -70[o]C Avoid freeze/thaw cycles.
- Hersteller:
- Cytion
- Typ:
- Cells: Cell Lines
- Datenblatt des Herstellers:019744b27ff57bb3a8262ca2ca1c2394